Adaptive Biotechnologies (ADPT) Misses Q1 Revs; Withdraws Guidance

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 revenue for the quarter came in at $20.9 million versus the consensus estimate of $22.66 million.

GUIDANCE:

“Adaptive’s immune medicine platform was built to decode the specific immune response to any disease, which we are now applying in full force to COVID-19,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “Importantly, we are able to do this while maintaining focus on our current products and future pipeline.”

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• Adeptus Biotechnologies Corp. (ADPT) PT Raised to $34 at BTIG
• Paychex (PAYX) Tops Q1 EPS by 2c
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance